Survival of patients with pulmonary arterial hypertension during therapy PAH-specific drugs
Pulmonary arterial hypertension (PAH) is a life threatening syndrome, which is characterized by a progressive increase in pulmonary vascular resistance (PVR), medium pulmonary artery pressure and functional disorders and morphological changes of pulmonary arteries. Despite the relative abundance of...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IP Morozov P.V.
2017-12-01
|
| Series: | Системные гипертензии |
| Subjects: | |
| Online Access: | https://syst-hypertension.ru/2075-082X/article/viewFile/29586/pdf |
| _version_ | 1818326570418307072 |
|---|---|
| author | D Yu Platonov N A Tsareva S N Avdeev |
| author_facet | D Yu Platonov N A Tsareva S N Avdeev |
| author_sort | D Yu Platonov |
| collection | DOAJ |
| description | Pulmonary arterial hypertension (PAH) is a life threatening syndrome, which is characterized by a progressive increase in pulmonary vascular resistance (PVR), medium pulmonary artery pressure and functional disorders and morphological changes of pulmonary arteries. Despite the relative abundance of PAH-specific drugs, the choice of a suitable agent for the treatment of a particular patient remains challenging. One of the most important parameters measured in clinical studies is patient survival or, in some cases, mortality. Survival or mortality as secondary or components of the primary endpoint one way or another has been studied in clinical trials of drugs for the treatment of PAH. For tablets drugs for the treatment of some forms of PAH (sildenafil, riociguat, bosentan, macitentan, ambrisentan) currently available data studies, which studied the survival. |
| first_indexed | 2024-12-13T12:02:29Z |
| format | Article |
| id | doaj.art-6a0d946f0827427083657794ffb53740 |
| institution | Directory Open Access Journal |
| issn | 2075-082X 2542-2189 |
| language | Russian |
| last_indexed | 2024-12-13T12:02:29Z |
| publishDate | 2017-12-01 |
| publisher | IP Morozov P.V. |
| record_format | Article |
| series | Системные гипертензии |
| spelling | doaj.art-6a0d946f0827427083657794ffb537402022-12-21T23:47:03ZrusIP Morozov P.V.Системные гипертензии2075-082X2542-21892017-12-01143586426614Survival of patients with pulmonary arterial hypertension during therapy PAH-specific drugsD Yu Platonov0N A Tsareva1S N Avdeev2Regional Clinical Hospital; Tver State Medical University of the Ministry of Health of the Russian FederationResearch Institute of Pulmonology of FMBA of Russia; I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian FederationResearch Institute of Pulmonology of FMBA of Russia; I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian FederationPulmonary arterial hypertension (PAH) is a life threatening syndrome, which is characterized by a progressive increase in pulmonary vascular resistance (PVR), medium pulmonary artery pressure and functional disorders and morphological changes of pulmonary arteries. Despite the relative abundance of PAH-specific drugs, the choice of a suitable agent for the treatment of a particular patient remains challenging. One of the most important parameters measured in clinical studies is patient survival or, in some cases, mortality. Survival or mortality as secondary or components of the primary endpoint one way or another has been studied in clinical trials of drugs for the treatment of PAH. For tablets drugs for the treatment of some forms of PAH (sildenafil, riociguat, bosentan, macitentan, ambrisentan) currently available data studies, which studied the survival.https://syst-hypertension.ru/2075-082X/article/viewFile/29586/pdfpulmonary hypertensionpah-specific therapysurvivalsildenafilriociguatbosentanmacitentanambrisentan |
| spellingShingle | D Yu Platonov N A Tsareva S N Avdeev Survival of patients with pulmonary arterial hypertension during therapy PAH-specific drugs Системные гипертензии pulmonary hypertension pah-specific therapy survival sildenafil riociguat bosentan macitentan ambrisentan |
| title | Survival of patients with pulmonary arterial hypertension during therapy PAH-specific drugs |
| title_full | Survival of patients with pulmonary arterial hypertension during therapy PAH-specific drugs |
| title_fullStr | Survival of patients with pulmonary arterial hypertension during therapy PAH-specific drugs |
| title_full_unstemmed | Survival of patients with pulmonary arterial hypertension during therapy PAH-specific drugs |
| title_short | Survival of patients with pulmonary arterial hypertension during therapy PAH-specific drugs |
| title_sort | survival of patients with pulmonary arterial hypertension during therapy pah specific drugs |
| topic | pulmonary hypertension pah-specific therapy survival sildenafil riociguat bosentan macitentan ambrisentan |
| url | https://syst-hypertension.ru/2075-082X/article/viewFile/29586/pdf |
| work_keys_str_mv | AT dyuplatonov survivalofpatientswithpulmonaryarterialhypertensionduringtherapypahspecificdrugs AT natsareva survivalofpatientswithpulmonaryarterialhypertensionduringtherapypahspecificdrugs AT snavdeev survivalofpatientswithpulmonaryarterialhypertensionduringtherapypahspecificdrugs |